<DOC>
	<DOCNO>NCT00694850</DOCNO>
	<brief_summary>The purpose study assess multiple ascend dose new drug ( BAY63-2521 ) give orally , evaluate safe help improve well-being , symptom ( e.g . disturbed breathe ) outcome pulmonary hypertension associate lung fibrosis . Patients live pulmonary hypertension associate interstitial lung disease risk increase number hospitalisation worsen condition . Until approved medication disease . The current treatment pulmonary hypertension associate interstitial lung disease consist : oxygen medical treatment vasodilator , e.g . so-called Calcium-antagonists . Therefore , need new drug treatment pulmonary hypertension associate interstitial lung disease .</brief_summary>
	<brief_title>Impact Multiple Doses BAY63-2521 Safety , Tolerability , Pharmacokinetics Pharmacodynamics Patients With Interstitial Lung Disease ( ILD ) Associated Pulmonary Hypertension ( PH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<criteria>Diagnosis interstitial lung disease ( usual interstitial pneumonia [ UIP ] , nonspecific interstitial pneumonia [ NSIP ] sarcoidosis ) high resolution CT total lung capacity ( TLC ) ≤ 90 % scleroderma associate pulmonary arterial hypertension ( PAH ) total lung capacity ( TLC ) ≤ 80 % . Interstitial lung disease ( ILD ) must stable least 3 month ( decrease force vital capacity ( FVC ) &lt; 10 % diffusing capacity lung carbon monoxide ( DLco ) &lt; 15 % 3 month ) , i.e . significant change pulmonary function test stable medication term ILD ( e.g. , corticosteroid , immunosuppressant ) Mean pulmonary vascular resistance ( PVR ) &gt; 400 dyne sec cm5 mean pulmonary arterial pressure ( PAP mean ) &gt; 30 mmHg Pulmonary capillary wedge pressure ( PCWP ) &lt; 15 mmHg Hemodynamic parameter baseline ( PAP , PCWP , cardiac output [ CO ] , systemic mean arterial pressure [ SAP ] ) High resolution computer tomography ( HRCT ) ( old 12 month prior start study ) Heart rate &gt; 55 beat per minute ( BPM ) &lt; 105 BPM rest Systolic blood pressure ( SBP ) &gt; 90 mmHg World Health Organisation ( WHO ) functional class II , III IV 6 Minute Walking Test ( 6MWT ) &gt; 100m &lt; 450 Stable control arterial hypertension accord current guideline Women childbearing potential include study pregnancy test negative combination condom safe highly effective contraception method ( hormonal contraception implant combine oral contraceptive , certain intrauterine device [ IUDs ] ) grant . Comedication : Patients pretreated specific medication pulmonary arterial hypertension ( PAH ) like endothelin receptor antagonist , prostaglandin phosphodiesterase type 5 ( PDE 5 ) blocker exclude trial . Requirement concomitant use nitrate contraindicate . Preexisting clinically relevant lung disease ILD include Bronchial asthma Chronic Obstructive Pulmonary Disease ( COPD ) force expiratory volume one second ( FEV1 ) /FVC &lt; 60 % pred. , active tuberculosis Pulmonary hypertension another WHO group ( I , II , IV V ) Severe congenital abnormality lung , thorax diaphragm Clinical radiological evidence pulmovenoocclusive disease ( PVOD ) Systemic hemodynamics Acute severe chronic leave heart failure ( ejection fraction ( EF ) &lt; 50 % ) Severe coronary artery disease ( CAD ; EF &lt; 50 % ) ; CAD patient must asymptomatic stable Congenital acquire valvular myocardial disease clinically significant apart tricuspid valvular insufficiency due pulmonary hypertension Pulmonary function TLC predict &lt; 30 % FEV1 ( related FVC ) &lt; 60 % predict Blood gas room air Arterial partial carbon dioxide pressure ( Pa CO2 ) &gt; 45 mmHg Arterial partial oxygen pressure ( Pa O2 ) &lt; 50 mmHg O2 supply &gt; /= 4 L/min Peripheral organ function Moderate severe hepatic insufficiency ( ChildPugh Class Band C and/or total bilirubin &gt; 2.5 mg/dl ( 0.043 mmol/L ) ; and/or hepatic transaminase &gt; 3 upper limit normal [ ULN ] ) Moderate severe renal insufficiency ( creatinine &gt; 2 mg/dl ) creatinine clearance accord CockroftGault formula &lt; 35 mL/ min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Interstitial lung disease associate pulmonary hypertension</keyword>
</DOC>